Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research ...

Use of alrizomadlin with pembrolizumab appeared to restore the antitumor effects of the anti-PD-1 antibody among patients with melanoma resistant to or intolerant of immunotherapy, according to ...

Nivolumab is another PD-1 inhibitor approved in 2014 for melanoma. Now, nivolumab treats patients with various cancers, including lung, kidney, and bladder cancers. Most recently, on March 4, 2022, ...

Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate ...

Results: A total of 135 patients were included; 65 patients received PD-1 inhibitors plus chemotherapy and radiotherapy, while other 70 patients were treated with immunochemotherapy alone. The median ...

One of the paper's co-authors, Hollings Cancer Center researcher Shikhar Mehrotra, Ph.D., previously found that PD-1 immunotherapy is not effective when there are high CD38 levels on T-cells.

But because the combination of this agent with anti—PD-1 immunotherapy has been shown to be tolerable, there are ongoing trials looking at this regimen, only in clinical trials, ...

The broad applicability of immunotherapy at this time for cancer is the PD-1 or PD-L1—blocking antibodies. By themselves, as single agents, they have very low toxicity profiles.

The therapy racked up a 33% increase in year-over-year sales in Q3 with $3.1 billion and is poised to become the first-ever biologic approved for chronic obstructive pulmonary disease, or COPD ...

immunotherapy PD-1 phosphatase Calico. A small molecule from AbbVie and Calico Life Sciences currently in early-stage clinical trials for solid tumors appears to improve the response to PD-1 ...

Anti–CTLA-4 (ipilimumab) has not been tested as a single agent for patients with NSCLC, but has some activity in combination with chemotherapy. 2,3 In combination with anti–PD-1/PD-L1, the ...